Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis

Hypertension

Volumn 30, Issue 6, 1997, Pages 1621-1627

  Takemoto, Masao ^a   Egashira, Kensuke ^a   Tomita, Hideharu ^a   Usui, Makoto ^a   Okamoto, Hiroshi ^b   Kitabatake, Akira ^b   Shimokawa, Hiroaki ^a   Sueishi, Katsuo ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Angiotensin; Bradykinin; Collagen hypertrophy; Endothelium derived factors; Remodeling

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLMESARTAN; TEMOCAPRIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATABOLISM; ENZYME INHIBITION; FIBROSIS; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; VASCULAR DISEASE;

EID: 0030717697     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.6.1621     Document Type: Article

References (37)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
2. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension. 1991;18(suppl III):III-115-III-121.
3. Loscarzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995;38:87-104.
4. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995; 38:105-128.
5. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
6. Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urahe Y, Takeshita A. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine. Circulation. 1993;88:77-81.
7. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, Takeshita A. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension. 1995;25:201-206.
8. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasodilation in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
9. Zeiher AM, Drexler H, Saubier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
10. Ho A, Egashira K, Kadokami T, Fukumoto Y, Takayanagi T, Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation. 1995;92:2636-2644.
11. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26(part 1):957-962.
12. Kadokami T, Egashira K, Kuwata K. Altered serotonin receptor subtypes contribute to microvascular hyperreactivity to serotonin in pigs with chronic inhibition of nitric oxide. Circulation. 1996;94: 182-189.
13. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 1992;90:647-652.
14. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-281.
15. Ribeiro MO, Antunes E, Nicci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 1992;20:298-303.
16. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278-287.
17. G-nitro-L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol. 1996;28: 142-148.
18. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-1828.
19. 1 receptor subtype. Circ Res. 1993;73:413-423.
20. Erdös EG. Angiotensin converting enzyme and the change in our concept through the years. Hypertension. 1990;26:363-370.
21. Oza NB, Schwartz JH, Goud HD, Levinsky NG. Rat aortic smooth muscle cell in culture express kallikrein kininogen and bradykininase activity. J Clin Invest. 1990;85:597-600.
22. Groves P, Kurz S, Just H, Drexler H. Role of bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
23. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H. Pharmacokinetics of temocapril an ACE inhibitor with preferential biliary excretion in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44:383-385.
24. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H. Pharmacology of CS-866 a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181-188.
25. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. HOE 140, a new potent and long-acting bradykinin antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
26. Farhy RD, Carretero OA, Ho KL, Scicli G. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
27. Cheung HS, Cushman DW. Inhibition of homogenous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Biophys Acta. 1973;293:451-463.
28. Hou J, Kato H, Cohen RA, Chobanian AV, Brecher P. Angiotensin II-induced cardiac fibrosis in rats is increased by chronic inhibition of nitric oxide synthase. J Clin Invest. 1995;96:2469-2477.
29. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92:562-578.
30. 1 angiotensin II receptor blockade on LV and myocyte function and structure with dilated cardiomyopathy. Circulation. 1994;90:I-III.
31. McDonald KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parish T, Stillman A, Cohn JN. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90:3034-3046.
32. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90: 1410-1422.
33. 1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation. 1997;95: 1592-1600.
34. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
35. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger AJ, Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250-259.
36. Linz W, Scholkens BA. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens. 1991;9:S400-S401.
37. Katoh M, Egashira K, Usui M. Cardiac angiotensin II receptors is increased in rats with cardiac remodeling induced by long-term blockade of nitric oxide synthesis. Circulation. 1996;94(suppl 1): I-656.